|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,927.50 GBX | -1.68% |
|
+0.94% | +5.65% |
| 08-10 | WINNERS & LOSERS: Threat to Vistry; Plus500 plans more share buybacks | AN |
| 08-06 | LifeMine Therapeutics, Inc. announced that it has received $188 million in funding from a group of investors | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 106B | |||||
| 1,057B | |||||
| 625B | - | - | - | ||
| 435B | |||||
| 363B | |||||
| 296B |
- Stock Market
- Stocks
- GSK Stock
- Charts GSK plc
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
